Funding to stop Candida auris lacking

A high proportion of people who have been diagnosed with C. auris have died


Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris, according to an article on the STAT News website.

Candida auris is making news for its ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

The head of mycotic diseases at the Centers for Disease Control and Prevention (CDC) acknowledged his field hasn’t attracted the same kind of research dollars as other pathogens.

A high proportion of people who have been diagnosed with C. auris have died — the CDC estimates it’s between 30 percent and 60 percent.

Read the article.



July 16, 2019


Topic Area: Infection Control


Recent Posts

Code Compliance Isn't Enough for Healthcare Resilience

Intensifying climate risks are pushing hospitals to think beyond code requirements and toward long-term resilience.


Ribbon Cutting Marks First Phase Completion for New Montefiore Einstein Facility

The second phase is expected to be completed in the second half of 2027.


Brooks Rehabilitation Launches 3 New Major Construction Projects

All three Jacksonville projects will begin construction in 2026 with plans to be completed in 2027 and early 2028.


Joint Commission Standards: What Updates Matter Most?

The latest revisions are streamlined and aligned with the Centers for Medicare and Medicaid Services, but the facility manager’s learning curve is steep.


Swinerton Completes Construction at Atlanta's Grady Hospital

Projects mark Swinerton’s first partnership with Georgia’s largest hospital.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.